5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: Phase I clinical and pharmacokinetic study

British Journal of Cancer

Volumn 88, Issue 8, 2003, Pages 1160-1167

  Rustin, G J S ^a   Bradley, C ^b   Galbraith, S ^a   Stratford, M ^c   Loadman, P ^d   Waller, S ^e   Bellenger, K ^e   Gumbrell, L ^e   Folkes, L ^c   Halbert, G ^f  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

^b BRADFORD ROYAL INFIRMARY   (United Kingdom)

^c Gray Cancer Institute   (United Kingdom)

^d UNIVERSITY OF BRADFORD   (United Kingdom)

^e IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^f UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

DMXAA; Pharmacodynamics; Pharmacokinetics; Toxicity

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; 5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; MITOMYCIN C; NITRIC OXIDE; NITROSOUREA; SEROTONIN; TAMOXIFEN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ANXIETY; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PAIN; CARCINOID; CLINICAL ARTICLE; CLINICAL TRIAL; COLOR VISION DEFECT; COLORECTAL CANCER; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELIRIUM; DELIRIUM TREMENS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG TARGETING; DRUG TOLERABILITY; DYSPHASIA; DYSPNEA; ESOPHAGUS CANCER; FEMALE; HEADACHE; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; HYPOTENSION; KIDNEY CANCER; KIDNEY PELVIS CARCINOMA; LUNG CANCER; MALAISE; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; METABOLITE; NAUSEA; OVARY CANCER; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SKIN IRRITATION; SLURRED SPEECH; SMALL INTESTINE CANCER; SOFT TISSUE SARCOMA; SWEATING; TREATMENT OUTCOME; URINE INCONTINENCE; UTERUS CANCER; VERTIGO; VISUAL DISORDER; VOMITING;

ADOLESCENT; ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CHILD; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; XANTHONES;

EID: 0038576231     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600885     Document Type: Article

References (38)

1. Baguley BC, Cole G, Thomsen LL, Zhuang L (1993) Serotonin involvement in the antitumour and host effects of flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol 3: 77-81
2. Baguley BC, Zhuang L, Kestell P (1997) Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethylxanthenone-4-acetic acid, vinblastine, and colchicine: relation to vascular effects. Oncology Res 9: 55-60
3. Cao Z, Joseph WR, Browne WL, Mountjoy KG, Palmer BD, Baguley BC, Ching LM (1999) Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 80: 716-723
4. Chaplin DJ, Pettit GR, Hill SA (1999) Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anticancer Res 19: 189-195
5. Ching LM, Joseph WR, Zhuang L, Baguley BC (1994) Induction of tumour necrosis factor-alpha messenger RNA in human and murine cells by the flavone acetic acid analogue 5,6-dimethylxanthenone-4-acetic acid (NSC 640488). Cancer Res 54: 870-872
6. Cliffe S, Taylor ML, Rutland M, Baguley BC, Hill RP, Wilson WR (1994) Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid. Int J Radiat Oncol Biol Phys 29: 373-377
7. Galbraith SM, Rustin GJS, Lodge MA, Taylor NJ, Stirling JJ, Jameson M, Thompson P, Hough D, Gumbrell L, Padhani A (2002) Effects of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) on human tumour microcirculation assessed by dynamic contrast enhanced magnetic resonance imaging (DCE-MRI). J Clin Oncol 20: 3826-3840
8. Hill SA, Lonergan SJ, Denekamp J, Chaplin DJ (1993) Vinca alkaloids: antivascular effects in a murine tumour. Eur J Cancer 29A: 1320-1324
9. Hill SA, Williams KB, Denekamp J (1989) Vascular collapse after flavone acetic acid: a possible mechanism of its antitumour action. Eur J Can Clln Oncol 25: 1419-1424
10. Hill SA, Williams KB, Denekamp J (1991) Studies with a panel of tumours having a variable sensitivity to FAA, to investigate its mechanism of action. Int J Radiat Biol 60: 379-384
11. Hill SA, Williams KB, Denekamp J (1992) A comparison of vascular-mediated tumor cell death by the necrotizing agents GR63178 and flavone acetic acid. Int J Radiat Oncol Biol Phys 22: 437-441
12. Horsman MR, Murata R, Overgaard J (1999) Improving conventional cancer therapy by targeting tumour vasculature. Br J Cancer 80: 247
13. Jameson MB, Thompson PI, Baguley BC, Evans BD, Harvey VJ, Porter DJ, McCrystal MR, Halbert GW, Kestell P (submitted) Phase I pharmacokinetic and pharmacodynamic study of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Eur J Cancer
14. Kanwar JR, Kanwar RK, Pandey S, Ching LM, Krissansen GW (2001) Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci. Cancer Res 61: 1948-1956
15. Kaye SB, Clavel M, Dodion P, Monfardini S, Tenbokkelhuinink W, Wagener DT, Gundersen S, Stoter G, Smith J, Renard J, Vanglabekke M, Cavalli F (1990) Phase II trials with flavone acetic acid (NSC-347512, LM975) in patients with advanced carcinoma of the breast, colon, head and neck and melanoma. Invest New Drugs 8: S95-S99
16. Kestell P, Zhao L, Jameson MB, Stratford MR, Folkes LK, Baguley BC (2001) Measurement of plasma 5-hydroxyindoleacetic acid as a possible clinical surrogate marker for the action of antivascular agents. Clin Chirn Acta 314: 159-166
17. Lash CJ, Li AE, Rutland M, Baguley BC, Zwi LJ, Wilson WR (1998) Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. Br J Cancer 78: 439-445
18. Laws AL, Matthew AM, Double JA, Bibby MC (1995) Preclinical in vitro and in vivo activity of 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 71: 1204-1209
19. Mahadevan V, Malik STA, Meager A, Fiers W, Lewis GP, Hart EI (1990) Role of tumour necrosis factor in flavone acetic acid-induced tumor vasculature shutdown. Cancer Res 50: 5537-5542
20. Miners JO, Valente L, Lillywhite KJ, Mackenzie PI, Burchell B, Baguley BC, Kestell P (1997) Preclinical prediction of factors influencing the elimination of 5,6-dimethylxanthenone-4-acetic acid, a new anticancer drug. Cancer Res 57: 284-289
21. Moilanen E, Thomsen LL, Miles DW, Happerfield DW, Knowles RG, Moncada S (1998) Persistent induction of nitric oxide synthase in tumours from mice treated with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 77: 426-433
22. Pedley RB, Sharma SK, Boxer GM, Boden R, Stribbling SM, Davies L, Springer CJ, Begent RH (1999) Enhancement of antibody-directed enzyme pro-drug therapy in colorectal xenografts by an antivascular agent. Cancer Res 59: 3998-4003
23. Philpott M, Baguley BC, Ching LM (1995) Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5,6-dimethlylxanthenone-4-acetic acid. Cancer Chemother Pharmacol 36: 143-148
24. Plowman J, Narayanan VL, Dykes D, Szarvasi E, Briet P, Yoder OC, Paull KD (1986) Flavone acetic acid: a novel agent with preclinical activity against colon adenocarcinoma 38 in mice. Cancer Treat Rep 70: 631-638
25. Pruijn FB, van Daalen M, Holford NH, Wilson WR (1997) Mechanisms of enhancement of the antitumour activity of melphalan by the tumour-blood-flow inhibitor 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol 39: 541-546
26. Rewcastle GW, Atwell GJ, Baguley BC, Calveley SB, Denny WA (1989) Potential antitumor agents. 58. Synthesis and structure-activity relationships of substituted xanthenone-4-acetic acids active against the colon 38 tumour in vivo. J Med Chem 32: 793-799
27. Rewcastle GW, Atwell GJ, Li ZA, Baguley BC, Denny WA (1991) Potential antitumor agents. 61. Structure activity relationships for in vivo colon-38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids. J Med Chem 34: 217-222
28. Siegenthaler P, Kaye SB, Monfardini S, Renard J (1992) Phase II trial with flavone acetic acid (NSC-347512, LM975) in patients with non-small cell lung cancer. Ann Oncol 3: 169-170
29. Smith GP, Calveley SB, Smith MJ, Baguley BC (1987) Flavone acetic acid (NSC 347512) induces haemorrhagic necrosis of mouse colon 26 and 38 tumours. Eur J Can Clin Oncol 23: 1209-1212
30. Stratford MRL (1999) Measurement of nitrite and nitrate by high-performance ion chromatography. In Nitric Oxide, Part C: Biological and Antioxidant Activities, Packer L (ed) pp 259-269. San Diego, CA: Academic Press
31. Thomsen LL, Ching LM, Zhuang L, Gavin JB, Baguley BC (1991) Tumor-dependent increased plasma nitrate concentrations as an indication of the antitumor effect of flavone-8-acetic acid and analogues in mice. Cancer Res 51: 77-81
32. Webster LK, Ellis AG, Kestell P, Rewcastle GW (1995) Metabolism and elimination of 5,6-dimethylxanthenone-4-acetic acid in the isolated perfused rat liver. Drug Metab Dispos 23: 363-368
33. Weiss RB, Green RF, Knight RD, Collins JM, Pelosi JJ, Sulkes A, Curt GA (1988) Phase I and clinical pharmacology study of intravenous flavone acetic acid (NSC-347512). Cancer Res 48: 5878-5882
34. Wilson WR, Baguley BC (2000) Combination of the antivascular agent DMXAA with radiation and chemotherapy. Int J Radiat Oncol Biol Phys 46: 706
35. Wilson WR, Li AE, Cowan DS, Simm BJ (1998) Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Int J Radiat Oncol Biol Phys 42: 905-908
36. Yamaoka K, Nakagawa T, Uno T (1978) Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharma 6: 165-175
37. Zwi LJ, Baguley BC, Gavin JB, Wilson WR (1994a) Correlation between immune and vascular activities of xanthenone acetic acid antitumor agents. Oncology Res 6: 79-85
38. Zwi LJ, Baguley BC, Gavin JB, Wilson WR (1994b) The morphological effects of the anti-tumor agents flavone acetic acid and 5,6-dimethyl xanthenone acetic acid on the colon 38 mouse tumor. Pathology 26: 161-169